Mycophenolate mofetil (MMF) therapeutic approach in patients with chronic glomerulonephritis (GN) [2]

Kidney International

Volumn 64, Issue 3, 2003, Pages 1139-

  Bullo, Barbara ^a   Zdrojewski, Zbigniew ^b   Rutkowski, Boleslaw ^b  

^a MEDICAL UNIVERSITY OF GDANSK   (Poland)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ALBUMIN; CORTICOSTEROID; CREATININE; CYCLOPHOSPHAMIDE; CYCLOSPORIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PROTEIN;

ADULT; CHRONIC GLOMERULONEPHRITIS; CLINICAL ARTICLE; DIAGNOSTIC APPROACH ROUTE; DOSE TIME EFFECT RELATION; DRUG EFFICACY; DRUG SAFETY; FEMALE; FOCAL GLOMERULOSCLEROSIS; HUMAN; INFECTION RISK; LETTER; LIPID METABOLISM; MALE; MEMBRANOPROLIFERATIVE GLOMERULONEPHRITIS; PRIORITY JOURNAL; PROTEINURIA;

EID: 0041429427     PISSN: 00852538     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1523-1755.2003.00180.x     Document Type: Letter

References (3)

1. LEVIN ML: Mycophenolate mofetil treatment for primary glomerular diseases. Kidney Int 62:1475, 2002
2. BRIGGS WA, CHOI MJ, SCHEEL PJ: Successful mycophenolate mofetil treatment of glomerular disease. Am J Kidney Dis 31:213-217, 1998
3. CHOI MJ, EUSTACE JA, GIMENEZ LF, et al: Mycophenolate mofetil treatment for primary glomerular diseases. Kidney Int 61:1098-1114, 2002